Making Safety Part of Drug Design
ApconiX has organised a free to attend, one day symposium on drug discovery safety at Magdalene College, Cambridge on the 12th of October. Speakers from GSK, SEDA Pharmaceutical Development Services, AstraZeneca, MSD, ApconiX and Newcells Biotech will deliver a broad scope of thought-provoking presentations.
The discovery and development of novel medicines with improved safety profiles are vital if we are to advance and expand treatment options available and improve outcomes for patients. Currently, safety issues in clinical development remain a major challenge to our industry and the time to reduce or eliminate potential safety liabilities is in the discovery phase while projects still have chemical choice.
This one day meeting will bring together experts in the field to consider different aspects of making safety an intrinsic part of drug design from target and chemical evaluation through to regulatory strategy. We are planning a full programme of short talks. The day will run from 9am to 5pm with lunch and refreshments provided throughout the day. The meeting will be highly relevant for pharma and biotech industry, academics and government scientists in the drug discovery and development field.
Invitations to register for the symposium will be sent out later in August. We look forward to welcoming you to this event.
One Day Symposium Programme
Cripps Court
Magdalene College
1-3 Chesterton Road
Arbury
Cambridge
CB4 3AD
October 12th 2023
Click here to download the programme
(subject to change)
| Time | Title | Speaker |
| 9-9:45 | Arrival and Registration with coffee and pastries | |
| 9:45-10 |
Introduction |
Professor Ruth Roberts, ApconiX |
| Opening Keynote | ||
| 10-10:30 | Reducing the Risk of Mitochondrially Active Compounds in Medicines Development | Dr Jon Lyon – Director of Preclinical Toxicity and Mitochondrial Network Lead, GSK |
| Morning Session | ||
| 10:30-11 | Assessing Cardiac Ion Channel Activity in the Drug Discovery Cascade | Dr Mike Morton, ApconiX |
| 11-11:30 | Making formulation part of drug design: case studies | Dr Linette Ruston, Director, ADME and Modelling Sciences, SEDA Pharmaceuticals |
| 11:30-12 | The role of Target Safety Assessments (TSAs) in derisking drug projects | Dr James Sidaway, ApconiX |
| 12-13 | Lunch Break | |
| Afternoon Session | ||
| 13-13:30 | Interfacing DMPK and Safety in Drug Design: Concentration effect relationships | Dr Kevin Beaumont, Senior Director, DMPK, AstraZeneca |
| 13:30-14 | Developing an ion channel seizure panel | Dr Kim Rockley, ApconiX |
| 14-14:30 | Designing out secondary pharmacology hits | Dr Mark Anderton, Senior Principal Scientist, MSD |
| 14:30-15 | Coffee/Tea | |
| 15-15:30 | State-of-the-art cellular models in de-risking drug design | Dr Colin Brown, Chief Innovation Officer, Newcells Biotech |
| 15:30-16 | Making safety part of drug design – a regulatory perspective | Dr David Jones, ApconiX |
| 16:00 | Panel discussion | Dr David Jones Dr Richard Knight Dr Anthony Holmes Dr Muireann Coen |
| 16:30 | Close |
Cripps Court is located just around the corner from the main porters lodge of Magdalene College on Chesterton Road in Cambridge City centre.